1. A 67-year-old woman with treatment-resistant depression requires a tricyclic antidepressant (TCA). Her past medical history includes benign prostatic hyperplasia in a male family member, but more relevantly she has a history of orthostatic syncope and mild cognitive slowing. Her psychiatrist wants to choose the TCA least likely to worsen these problems. Which structural classification of TCA best predicts a lower burden of anticholinergic and alpha-1 adrenergic adverse effects, and which agent exemplifies this class?

• A) Tertiary amine TCAs, because their two methyl groups on the terminal nitrogen increase lipophilicity and CNS penetration while paradoxically reducing peripheral receptor binding affinity at muscarinic and alpha-1 sites
• B) Tertiary amine TCAs, because demethylation to secondary amine metabolites occurs so rapidly that the patient is effectively exposed only to the secondary amine within hours of dosing, rendering the tertiary/secondary distinction clinically irrelevant
• C) Secondary amine TCAs, because removal of one methyl group from the terminal nitrogen reduces muscarinic anticholinergic and alpha-1 adrenergic receptor binding potency relative to tertiary amines; nortriptyline is the prototypical secondary amine with the best-characterized tolerability and therapeutic window
• D) Secondary amine TCAs, because their lower lipophilicity relative to tertiary amines reduces CNS penetration and eliminates central anticholinergic effects entirely while preserving full peripheral antidepressant efficacy through NET inhibition
• E) The tertiary/secondary amine distinction does not predict receptor binding selectivity; adverse effect burden is determined solely by dose and individual CYP2D6 metabolizer status rather than by structural classification

2. A 44-year-old man of Northern European ancestry is started on nortriptyline 75 mg nightly for treatment-resistant depression. After six weeks at this dose his plasma nortriptyline level is 340 ng/mL (therapeutic range 50 to 150 ng/mL) despite no interacting medications. He reports significant dry mouth, constipation, and confusion. No dose changes have occurred. Which pharmacogenomic explanation best accounts for this clinical picture?

• A) The patient is likely a CYP2D6 poor metabolizer (PM); CYP2D6 is the principal enzyme responsible for nortriptyline clearance, and PM individuals accumulate markedly elevated plasma concentrations at standard doses due to substantially reduced metabolic clearance, placing them at risk for concentration-dependent toxicity
• B) The patient is likely a CYP2D6 ultra-rapid metabolizer (UM); ultra-rapid metabolizers generate excessive quantities of the active secondary amine metabolite desipramine from nortriptyline, and it is desipramine accumulation rather than nortriptyline accumulation that produces the toxic plasma level reported
• C) The patient is likely a CYP3A4 poor metabolizer; CYP3A4 is the primary isoform responsible for nortriptyline demethylation, and loss-of-function variants in CYP3A4 are the most common cause of supratherapeutic TCA levels in patients of European ancestry
• D) The patient is likely a CYP2C19 ultra-rapid metabolizer; ultra-rapid CYP2C19 activity converts nortriptyline to a pharmacologically inactive N-oxide metabolite at an accelerated rate, paradoxically increasing the apparent plasma concentration measured by standard immunoassay due to cross-reactivity
• E) The patient is likely a P-glycoprotein (P-gp) loss-of-function variant carrier; reduced P-gp efflux at the blood-brain barrier allows nortriptyline to accumulate in the CNS at concentrations disproportionate to plasma levels, producing central toxicity despite a plasma level that would otherwise be sub-therapeutic

3. A 58-year-old man with recurrent major depressive disorder is being monitored on nortriptyline. His psychiatrist notes that this drug has a well-characterized plasma concentration-response relationship that distinguishes it from most other antidepressants, and that the relationship has an important implication: increasing the dose beyond the upper boundary of the therapeutic window does not simply plateau in effect but produces a different clinical outcome. Which of the following correctly describes nortriptyline's plasma concentration-response relationship and its clinical implications?

• A) Nortriptyline has a linear dose-response relationship with antidepressant efficacy increasing proportionally with plasma concentration up to a ceiling effect at approximately 300 ng/mL, above which further dose increases produce no additional antidepressant benefit but also no increase in adverse effects until toxic concentrations exceed 500 ng/mL
• B) Nortriptyline has a threshold-dependent response in which no antidepressant effect is observed below 50 ng/mL, full antidepressant response is achieved at any concentration above this threshold up to the toxicity boundary, and plasma level monitoring is therefore useful only for detecting sub-therapeutic concentrations rather than for titrating within the therapeutic range
• C) Nortriptyline has a flat dose-response relationship within the therapeutic range with antidepressant efficacy equivalent at 50 ng/mL and at 150 ng/mL; plasma level monitoring is indicated primarily to detect CYP2D6 drug interactions and poor metabolizer accumulation rather than to guide dose optimization within the established range
• D) Nortriptyline's therapeutic plasma range of 150 to 300 ng/mL reflects the combined measurement of parent drug plus its active desipramine metabolite; monitoring the parent nortriptyline fraction alone is unreliable because inter-individual variation in demethylation rates means the nortriptyline fraction can be as low as 20% of the combined total
• E) Nortriptyline has a curvilinear (inverted-U) plasma concentration-response relationship with a therapeutic window of 50 to 150 ng/mL; antidepressant efficacy increases as concentrations rise toward the middle of this range but decreases at supra-therapeutic concentrations above 150 ng/mL, meaning that dose increases beyond the therapeutic window worsen rather than improve outcomes

4. A 19-year-old woman presents to the emergency department 90 minutes after ingesting an unknown quantity of amitriptyline. She is drowsy with a GCS of 13. Her initial ECG shows a QRS of 88 ms. Over the next 30 minutes the QRS widens to 108 ms. The attending orders sodium bicarbonate. A medical student asks the attending to explain (1) what QRS thresholds guide management decisions in TCA overdose, and (2) why sodium bicarbonate -- not an antiarrhythmic -- is the correct treatment. Which of the following correctly answers both questions?

• A) A QRS exceeding 120 ms is the threshold for sodium bicarbonate in TCA overdose; bicarbonate works by creating an alkaline urine pH that traps the ionized form of TCA in the renal tubule, preventing reabsorption and accelerating renal elimination of the drug
• B) A QRS exceeding 100 ms predicts seizure risk and is the threshold for sodium bicarbonate; a QRS exceeding 160 ms predicts high risk of ventricular arrhythmia; bicarbonate works through two mechanisms: alkalinization to pH 7.45--7.55 reduces TCA binding affinity for the cardiac sodium channel, and the sodium load increases the electrochemical gradient driving sodium into myocytes to partially overcome the channel block
• C) A QRS exceeding 80 ms is the treatment threshold in TCA overdose because this represents the upper limit of normal and any sodium channel blockade warrants immediate alkalinization; bicarbonate works exclusively through its sodium content -- the alkalinization itself is irrelevant and the same benefit could be achieved with hypertonic saline alone
• D) A QRS exceeding 100 ms triggers immediate endotracheal intubation regardless of mental status; sodium bicarbonate is contraindicated once QRS exceeds 100 ms because alkalemia above pH 7.45 shifts the oxyhemoglobin dissociation curve leftward and impairs tissue oxygen delivery in the already hemodynamically compromised patient
• E) QRS duration is a poor predictor of arrhythmia risk in TCA overdose and the QTc interval is the primary ECG metric; sodium bicarbonate is indicated only when QTc exceeds 500 ms and works by blocking cardiac potassium channels to shorten repolarization and reduce torsades de pointes risk

5. A 72-year-old man with suspected imipramine overdose is agitated, incoherent, tachycardic at 118 bpm, with dilated pupils and dry flushed skin. His QRS is 116 ms. A consultant suggests physostigmine to rapidly reverse the anticholinergic delirium. Which of the following correctly identifies the pharmacological reason physostigmine is contraindicated in this setting, and correctly contrasts it with a structurally similar agent that lacks this problem?

• A) Physostigmine is contraindicated because it is a quaternary ammonium compound that cannot cross the blood-brain barrier, meaning it would reverse peripheral cholinergic blockade (worsening urinary retention and GI motility) without treating the central delirium, producing a worse clinical picture; neostigmine, a tertiary amine, would be the appropriate agent for reversing central anticholinergic effects
• B) Physostigmine is contraindicated because it irreversibly inhibits acetylcholinesterase; in the setting of TCA overdose the resulting permanent cholinergic excess cannot be titrated and produces uncontrollable bradycardia; edrophonium, a reversible inhibitor with an ultrashort duration, is the appropriate alternative when central anticholinergic reversal is required
• C) Physostigmine is contraindicated because it inhibits CYP2D6, the primary metabolizing enzyme for imipramine, causing a pharmacokinetic interaction that raises imipramine plasma concentrations by 40% to 60% within two hours of administration; bethanechol, a direct muscarinic agonist, avoids this interaction while reversing peripheral anticholinergic symptoms
• D) Physostigmine is a tertiary amine cholinesterase inhibitor that does cross the blood-brain barrier and can reverse central anticholinergic effects, but in the setting of TCA-induced cardiac sodium channel blockade it is contraindicated because the enhanced acetylcholine it generates at the sinoatrial node and cardiac conduction system increases vagal tone and risks bradycardia or asystole; neostigmine, a quaternary ammonium compound that does not cross the blood-brain barrier, avoids the central cholinergic reversal but also cannot help the delirium
• E) Physostigmine is contraindicated because it directly blocks cardiac fast sodium channels through a mechanism additive with TCA-induced sodium channel blockade, producing QRS widening equivalent to an additional TCA dose; pyridostigmine is the appropriate alternative because its peripheral restriction prevents it from reaching the cardiac conduction system

6. A pharmacologist is explaining to residents why non-selective irreversible MAOIs carry a dietary tyramine restriction while selective MAO-B inhibitors at low doses do not. The explanation hinges on the substrate specificity of MAO isoforms in the gut and liver. Which of the following correctly describes the isoform responsible for first-pass tyramine metabolism, and why its inhibition is the critical determinant of the dietary interaction?

• A) MAO-A is the isoform primarily responsible for tyramine first-pass metabolism in the intestinal mucosa and liver; when MAO-A is irreversibly inhibited by phenelzine or tranylcypromine, dietary tyramine bypasses first-pass extraction entirely and reaches the systemic circulation intact, where it acts as an indirect sympathomimetic to trigger massive norepinephrine release from adrenergic nerve terminals
• B) MAO-B is the isoform primarily responsible for tyramine first-pass metabolism in the intestinal mucosa and liver; selective MAO-B inhibitors such as low-dose selegiline therefore fully impair tyramine first-pass extraction, which is why patients on low-dose selegiline require the same dietary restrictions as those on non-selective irreversible MAOIs
• C) Both MAO-A and MAO-B contribute equally to tyramine first-pass metabolism in the gut; inhibition of either isoform alone reduces first-pass extraction by exactly 50%, meaning that dietary tyramine restriction is required for both selective MAO-A and selective MAO-B inhibitors and is only abolished when neither isoform is inhibited
• D) MAO-A handles tyramine catabolism exclusively within the CNS, while MAO-B handles all peripheral (gut and hepatic) tyramine metabolism; this anatomical segregation means that dietary tyramine restriction is determined by MAO-B inhibition status, not MAO-A inhibition status
• E) Neither MAO-A nor MAO-B is primarily responsible for tyramine first-pass extraction; tyramine is instead catabolized in the gut by catechol-O-methyltransferase (COMT), and the dietary restriction associated with MAOIs reflects impaired hepatic COMT activity rather than impaired MAO-catalyzed deamination

7. A resident is counseling a patient on phenelzine about the two-week washout requirement before any serotonergic drug can be started after stopping phenelzine. The patient asks: "But if the drug is out of my system in a few days, why do I need to wait two weeks?" Which of the following correctly explains the mechanistic basis for the dissociation between phenelzine's plasma elimination half-life and the duration of its pharmacodynamic effect?

• A) Phenelzine's plasma half-life is a poor predictor of its duration of action because phenelzine undergoes extensive redistribution from plasma into neuronal lipid membranes, from which it is released slowly over two weeks; the drug is pharmacologically active throughout this redistribution phase despite being undetectable in plasma
• B) Phenelzine is converted to a long-lived active metabolite, phenylethylhydrazine, with a plasma half-life of approximately 14 days; it is this metabolite -- not the parent drug -- that sustains MAO inhibition throughout the two-week period, and plasma clearance of the parent compound is clinically irrelevant to the washout calculation
• C) Phenelzine forms a covalent bond with the flavin adenine dinucleotide (FAD) cofactor of monoamine oxidase, permanently inactivating the enzyme; once inactivated, MAO cannot be restored by any pharmacological means -- recovery depends entirely on synthesis of new enzyme protein, which takes approximately two weeks, so the pharmacodynamic effect persists long after the drug has been cleared from plasma
• D) Phenelzine's two-week effect duration reflects its unusually high plasma protein binding (greater than 99%), which creates a large reservoir of bound drug that is released only slowly as unbound drug is eliminated; the free fraction available for receptor interaction persists at pharmacologically active concentrations for approximately 14 days after the last dose
• E) The two-week washout is a conservative regulatory requirement that exceeds the actual pharmacodynamic duration; MAO activity is substantially restored within four to five days of stopping phenelzine, and the additional nine to ten days represent a safety margin applied to account for population variability in enzyme resynthesis rates rather than the expected recovery time in most patients

8. A patient on tranylcypromine is being switched to venlafaxine for inadequate antidepressant response. The psychiatrist calculates the required washout interval before starting venlafaxine. A student asks why the washout for tranylcypromine differs from the washout required when stopping most SSRIs before starting an MAOI, and why the calculation uses a different variable in each direction. Which of the following correctly explains the asymmetry between these two washout calculations?

• A) The washout after stopping tranylcypromine before starting venlafaxine is two weeks, determined by the plasma elimination half-life of tranylcypromine (approximately seven days); the washout after stopping venlafaxine before starting an MAOI is one week, determined by the plasma elimination half-life of venlafaxine and its active metabolite desvenlafaxine
• B) The washout after stopping tranylcypromine is one week because tranylcypromine's acetylated metabolite, which retains partial MAO inhibitory activity, has a plasma half-life of approximately seven days; the washout after stopping venlafaxine is two weeks because venlafaxine upregulates MAO-A expression during treatment, and two weeks is required for MAO-A expression to return to baseline
• C) Both washout directions require two weeks; the calculation is symmetric because the serotonin syndrome risk arises from the same pharmacodynamic state -- excessive synaptic serotonin -- regardless of which agent is stopped first, so the interval is identical in both directions and is determined by the slower pharmacokinetic variable in either case
• D) The washout after stopping venlafaxine before starting an MAOI is two weeks, determined by the time for venlafaxine and desvenlafaxine to be cleared from plasma (five half-lives of the longer-lived species); the washout after stopping tranylcypromine before starting venlafaxine is also two weeks but is determined by MAO enzyme resynthesis time -- not by plasma clearance of tranylcypromine, which is cleared within days
• E) The washout after stopping tranylcypromine before starting venlafaxine is two weeks, determined not by tranylcypromine's plasma half-life but by the time required for new MAO enzyme to be synthesized after irreversible covalent inactivation; the washout after stopping venlafaxine before starting an MAOI is approximately one week, determined by plasma clearance of venlafaxine and its active metabolite desvenlafaxine (five half-lives of the longer-lived species)

9. A neurologist prescribes selegiline 5 mg orally twice daily to a patient with early Parkinson's disease. A psychiatrist colleague later considers using selegiline for a patient with treatment-resistant depression and notes that the drug must be used at a much higher dose and via a different route to achieve antidepressant effect. The psychiatrist also notes that the transdermal formulation at its lowest approved dose carries a different dietary restriction requirement than oral selegiline at antidepressant doses. Which of the following correctly explains all three of these distinctions?

• A) Oral selegiline at low doses (5 to 10 mg) is a non-selective inhibitor of both MAO-A and MAO-B; at higher oral antidepressant doses the drug shifts to selective MAO-B inhibition as MAO-A binding sites become saturated; the transdermal route delivers drug at a rate that maintains MAO-B selectivity systemically while still achieving therapeutic antidepressant plasma concentrations
• B) Oral selegiline at low doses (5 to 10 mg) selectively inhibits MAO-B, providing antiparkinsonian benefit without significant antidepressant effect because MAO-A inhibition is required for antidepressant efficacy; at higher oral doses MAO-B selectivity is lost and MAO-A is also inhibited, producing antidepressant effect but requiring dietary tyramine restriction; the transdermal formulation at 6 mg per 24 hours achieves antidepressant-level systemic MAO inhibition while bypassing first-pass gut and liver MAO-A, substantially preserving tyramine first-pass extraction and reducing the dietary restriction requirement
• C) Oral selegiline at all doses preferentially inhibits MAO-A in the gut and liver due to the high concentration of MAO-A at these sites during first-pass absorption; the transdermal route avoids gut MAO-A entirely by delivering drug directly into the systemic circulation, which paradoxically allows higher CNS drug concentrations at lower total doses; the 6 mg transdermal dose achieves full non-selective MAO inhibition systemically with no dietary restriction requirement at any dose
• D) The antiparkinsonian and antidepressant doses of selegiline are identical; the neurologist uses a lower dose solely for tolerability, not for pharmacodynamic reasons; the transdermal formulation has a dietary restriction exemption at the lowest dose because the patch releases drug at a rate below the threshold for any MAO inhibition, and the antidepressant effect at 6 mg is achieved through a non-MAO dopaminergic mechanism
• E) Oral selegiline at all doses is a selective MAO-B inhibitor; it achieves antidepressant effect at standard doses through dopamine pathway enhancement without requiring MAO-A inhibition; the transdermal formulation requires dietary restriction at all doses because transdermal delivery saturates both MAO-A and MAO-B in the gut mucosa during absorption through dermal capillaries that drain into the portal system

10. A Canadian psychiatrist describes moclobemide to a group of American residents who are unfamiliar with the drug. She explains that it represents a mechanistically distinct approach to MAO inhibition compared to phenelzine and tranylcypromine, and that its mechanism accounts for three clinical differences: reduced dietary tyramine restriction, a shorter washout period before switching to serotonergic agents, and its regulatory status in the United States. Which of the following correctly characterizes moclobemide's mechanism and all three of these clinical implications?

• A) Moclobemide is a selective irreversible MAO-A inhibitor; its selectivity for MAO-A over MAO-B allows dietary tyramine to be metabolized by residual MAO-B in the gut, reducing the pressor response risk; the shorter washout of 48 to 72 hours reflects faster MAO-A enzyme resynthesis compared to MAO-B; it is not FDA-approved because MAO-A-selective irreversible inhibitors are considered higher risk than non-selective agents in the US regulatory framework
• B) Moclobemide is a reversible inhibitor of MAO-B (RIMB); because MAO-A is uninhibited, dietary tyramine first-pass extraction is fully preserved and no restriction is required; the 24-hour washout reflects rapid restoration of MAO-B activity; it received FDA approval in 2001 but was withdrawn due to post-marketing reports of hypertensive crisis indistinguishable from that seen with irreversible agents
• C) Moclobemide is a non-selective reversible MAO inhibitor that inhibits both MAO-A and MAO-B competitively; dietary restriction is still required because both isoforms are inhibited simultaneously; the 24-hour washout is shorter than irreversible agents solely because the plasma half-life of moclobemide is approximately six hours; it is approved by the FDA for atypical depression under the trade name Manerix
• D) Moclobemide is a reversible inhibitor of MAO-A (RIMA); high concentrations of dietary tyramine can competitively displace moclobemide from the MAO-A active site, partially restoring enzyme activity and substantially reducing the tyramine pressor response risk; the washout before serotonergic drugs is approximately 24 hours because MAO activity recovers rapidly after stopping a reversible inhibitor without requiring new enzyme synthesis; moclobemide is not FDA-approved in the United States and is used clinically in Canada, Europe, and Australia
• E) Moclobemide is a selective MAO-B inhibitor whose antidepressant mechanism at therapeutic doses depends entirely on dopamine enhancement rather than on MAO-A inhibition; dietary tyramine restriction is unnecessary because all tyramine metabolism is handled by MAO-A, which is uninhibited; the 24-hour washout reflects rapid plasma clearance; it is not FDA-approved because it was developed after the current FDA approval pathway made MAOI approval commercially non-viable for manufacturers

11. A 49-year-old woman on phenelzine eats a large portion of aged Gruyere cheese and develops a pounding headache, diaphoresis, and a blood pressure of 224/130 mmHg within 45 minutes. A medical student asks why tyramine -- a dietary amine, not a catecholamine -- can produce such severe hypertension. Which of the following correctly describes the complete intracellular sequence by which tyramine produces this pressor response?

• A) Tyramine bypasses MAO-A first-pass extraction, enters the systemic circulation intact, and is actively transported into peripheral adrenergic nerve terminals by the norepinephrine transporter (NET); once inside the terminal, tyramine enters synaptic vesicles and displaces stored norepinephrine into the synapse through a vesicular exchange mechanism, producing massive norepinephrine overflow that activates alpha-1 adrenergic receptors on resistance vessels and causes acute severe hypertension
• B) Tyramine bypasses MAO-A first-pass extraction and circulates intact; it then binds directly to postsynaptic alpha-1 adrenergic receptors at peripheral vascular smooth muscle as a full agonist with affinity approximately equal to norepinephrine, producing vasoconstriction; its prolonged duration of pressor effect compared to norepinephrine reflects its resistance to metabolism by catechol-O-methyltransferase (COMT)
• C) Tyramine is converted to octopamine in the systemic circulation by the enzyme dopamine beta-hydroxylase; octopamine is a false neurotransmitter that enters adrenergic nerve terminals via NET, displaces norepinephrine from vesicles, and co-releases with norepinephrine; octopamine has lower intrinsic alpha-1 potency than norepinephrine but its massive release volume overwhelms the reduced per-molecule potency to produce net hypertension
• D) Tyramine activates presynaptic trace amine-associated receptor 1 (TAAR1) on adrenergic nerve terminals; TAAR1 activation triggers a Gs-coupled signaling cascade that phosphorylates the vesicular monoamine transporter 2 (VMAT2), causing it to expel its entire norepinephrine content into the cytoplasm, from which norepinephrine passively diffuses across the axonal membrane into the synapse via concentration-gradient-driven efflux
• E) Tyramine is deaminated in the systemic circulation to p-hydroxyphenylacetaldehyde by circulating monoamine oxidase in platelets; this reactive aldehyde intermediate directly damages adrenergic nerve terminal membranes, causing uncontrolled norepinephrine leakage from disrupted vesicles and producing the hypertensive crisis through a cytotoxic rather than pharmacodynamic mechanism

12. A 36-year-old woman presents with a two-year history of depression characterized by moods that brighten transiently when she receives good news, sleeping 13 hours per night on weekends, gaining 18 pounds over the past year with pronounced carbohydrate cravings, describing her limbs as feeling "like they are filled with lead," and experiencing severe distress when she perceives rejection by friends or colleagues. She has failed adequate trials of sertraline and escitalopram. Which antidepressant class has the most robust clinical trial evidence for superiority specifically in this depressive subtype, and what is the evidence base?

• A) SNRIs such as venlafaxine, because dual serotonin and norepinephrine reuptake inhibition addresses both the serotonergic deficit underlying mood reactivity and the noradrenergic deficit underlying leaden paralysis and hypersomnia; multiple meta-analyses of SNRI trials have demonstrated superiority over SSRIs specifically in the atypical depression subtype
• B) Mirtazapine, because its combined alpha-2 autoreceptor blockade and histamine H1 antagonism simultaneously increases norepinephrine and serotonin release while producing the sedation and appetite stimulation that address hypersomnia and hyperphagia; randomized trials in atypical depression have shown mirtazapine superiority over both SSRIs and TCAs in this subtype
• C) MAOIs, specifically phenelzine, which demonstrated superiority over imipramine and over placebo in randomized controlled trials specifically in atypical depression as defined by mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity; this evidence base, established by Liebowitz and colleagues and subsequently replicated, makes MAOIs the most strongly evidence-supported pharmacological treatment for this subtype
• D) Bupropion, because its selective dopamine and norepinephrine reuptake inhibition without serotonergic activity provides a mechanistically distinct approach; the leaden paralysis, hypersomnia, and hyperphagia of atypical depression reflect dopamine pathway dysfunction in reward and arousal circuits, and multiple head-to-head trials have demonstrated bupropion superiority over SSRIs and TCAs specifically in this subtype
• E) TCAs such as imipramine, which demonstrated superiority over MAOIs and over placebo in the landmark Columbia University trials of atypical depression; TCAs are now considered first-line for atypical depression when SSRIs have failed, ahead of MAOIs, because their more favorable safety profile -- particularly the absence of dietary restrictions -- makes them a more practical choice for the majority of outpatients

13. A 61-year-old man on phenelzine is admitted for emergency appendectomy. The anesthesiologist needs to select a safe opioid analgesic for intraoperative and postoperative pain management. A nurse asks whether all opioids carry the same interaction risk with MAOIs or whether some are safer than others. Which of the following correctly identifies the opioid that is absolutely contraindicated with irreversible MAOIs, the mechanism of its interaction, and an opioid that is considered a safer alternative?

• A) Morphine is absolutely contraindicated with irreversible MAOIs because it is a potent MAO-A substrate that accumulates to toxic concentrations when MAO-A is inhibited; fentanyl carries the same risk because all mu-opioid receptor agonists are metabolized by MAO-A; tramadol is the only opioid safe for use in MAOI-treated patients because it is eliminated exclusively by renal excretion without MAO involvement
• B) Codeine is absolutely contraindicated with irreversible MAOIs because CYP2D6-mediated conversion of codeine to morphine is markedly accelerated when MAOI-induced MAO-A inhibition alters hepatic redox state; fentanyl is contraindicated for the same reason; hydromorphone is the preferred opioid because it bypasses CYP2D6 conversion and is not a SERT inhibitor
• C) Tramadol is absolutely contraindicated with irreversible MAOIs because it is a potent MAO-A substrate that is catabolized under normal conditions by MAO-A before reaching opioid receptors; accumulation during MAOI therapy produces opioid toxicity characterized by miosis, respiratory depression, and bradycardia; hydrocodone is considered a safe alternative because it has no MAO-A substrate activity
• D) Fentanyl is absolutely contraindicated with irreversible MAOIs because its N-dealkylation product norfentanyl is a selective MAO-B inhibitor that competitively amplifies the phenelzine effect; morphine is preferred because it is metabolized entirely by glucuronidation and has no pharmacokinetic interaction with the MAO system; meperidine should also be avoided because of its indirect sympathomimetic properties
• E) Meperidine is absolutely contraindicated with irreversible MAOIs because it inhibits serotonin reuptake through the serotonin transporter (SERT) in addition to its mu-opioid receptor agonism; the combination of SERT inhibition with MAO-A inhibition produces a serotonin syndrome variant characterized by hyperthermia, agitation, and rigidity; morphine and fentanyl are considered safer alternatives because they lack significant SERT inhibitory activity; dextromethorphan carries a similar MAOI interaction risk through its own serotonergic properties

14. A psychiatrist is planning a switch from an SSRI to phenelzine in a patient with treatment-resistant atypical depression. The patient has been on fluoxetine 40 mg daily for 18 months. A colleague asks why the required washout before phenelzine differs from the washout required after stopping sertraline or paroxetine before initiating an MAOI. Which of the following correctly identifies the fluoxetine-specific washout interval and the pharmacokinetic property that mandates it?

• A) The required washout after fluoxetine before phenelzine is two weeks -- the same as after sertraline or paroxetine -- because all SSRIs inhibit SERT reversibly and the duration of serotonergic activity after any SSRI is determined by plasma clearance, which follows similar first-order kinetics for all agents in this class at five half-lives
• B) The required washout after fluoxetine before phenelzine is five weeks; fluoxetine is metabolized to norfluoxetine, an active metabolite with a plasma half-life of one to two weeks; five weeks is required to clear both parent drug and active metabolite to sub-pharmacological concentrations and eliminate the serotonin syndrome risk before introducing irreversible MAO-A inhibition
• C) The required washout after fluoxetine before phenelzine is eight weeks; fluoxetine irreversibly inhibits SERT, and SERT receptor resynthesis requires approximately eight weeks to restore transporter density to pre-treatment baseline; only after SERT density has normalized is it safe to introduce an irreversible MAOI
• D) The required washout after fluoxetine before phenelzine is three weeks; fluoxetine undergoes saturable (zero-order) elimination at therapeutic doses because it saturates its own CYP2D6 metabolizing enzyme, extending the elimination phase by approximately one additional week beyond the two-week standard SSRI washout
• E) The required washout after fluoxetine before phenelzine is four weeks; fluoxetine's active metabolite norfluoxetine irreversibly inhibits CYP2C19, and four weeks is required for new CYP2C19 enzyme synthesis; until CYP2C19 is restored, phenelzine cannot be adequately metabolized and accumulates to toxic concentrations

15. A toxicologist is consulted on a patient with severe desipramine overdose and a QRS of 142 ms. A nephrology fellow proposes urgent hemodialysis to enhance drug removal and asks the toxicologist to also clarify the mechanism of sodium bicarbonate therapy currently being administered. The toxicologist explains why hemodialysis is not useful and describes the two distinct pharmacological mechanisms by which sodium bicarbonate reverses cardiac toxicity. Which of the following correctly explains both points?

• A) Hemodialysis is ineffective because desipramine undergoes rapid phase II glucuronidation that converts it to a large polar conjugate exceeding the molecular weight cutoff of dialysis membranes; sodium bicarbonate works by providing a bicarbonate anion that directly competes with desipramine at the cardiac sodium channel binding site, displacing the drug and restoring normal channel function
• B) Hemodialysis is ineffective because desipramine is eliminated exclusively by biliary excretion into the gastrointestinal tract, and extracorporeal clearance of drug from plasma does not interrupt this enterohepatic cycle; sodium bicarbonate works by inhibiting CYP2D6 at alkaline pH, reducing ongoing desipramine formation from imipramine and thereby limiting further accumulation
• C) Hemodialysis is ineffective in patients with normal renal function because TCAs are primarily renally cleared, and hemodialysis can only supplement -- not replace -- tubular secretion mechanisms that require intact nephrons; sodium bicarbonate works by alkalinizing urine to trap ionized TCA in the tubular lumen, enhancing the renal excretion that hemodialysis cannot replicate
• D) Hemodialysis is ineffective because desipramine has a very large volume of distribution (10 to 50 liters per kilogram), meaning that the vast majority of total body drug is sequestered in peripheral tissues and the myocardium, leaving only a negligible fraction in the plasma compartment accessible to dialysis; sodium bicarbonate works through two mechanisms: alkalinization of blood to pH 7.45 to 7.55 reduces desipramine's binding affinity for the cardiac sodium channel, and the accompanying sodium load increases the electrochemical driving force for sodium entry into myocytes during phase 0, partially compensating for channel blockade
• E) Hemodialysis is moderately effective for desipramine removal because desipramine has lower lipophilicity than tertiary amine TCAs and therefore a smaller volume of distribution (approximately 2 to 4 liters per kilogram) that allows meaningful plasma clearance by high-flux membranes; sodium bicarbonate is the preferred adjunct because its alkalinization prevents new desipramine distribution from plasma into tissue compartments during the dialysis session

16. A clinical pharmacist flags an amitriptyline prescription for an 81-year-old man with depression and chronic low back pain, citing the Beers Criteria as the basis for the alert. The prescribing physician asks the pharmacist to explain the specific pharmacological mechanisms underlying the Beers Criteria listing for TCAs in older adults, beyond simply "they have side effects." Which of the following correctly identifies the two receptor-based mechanisms that make TCAs particularly dangerous in elderly patients and explains why age amplifies each risk?

• A) Blockade of muscarinic acetylcholine receptors produces confusion, delirium, urinary retention, and constipation -- risks amplified in the elderly by age-related reduction in CNS cholinergic reserve, increased prevalence of genitourinary outflow obstruction, and decreased baseline gut motility; blockade of alpha-1 adrenergic receptors at peripheral resistance vessels produces orthostatic hypotension and syncope -- risks amplified by age-related baroreceptor reflex impairment, reduced cardiovascular compensatory reserve, and polypharmacy with antihypertensives that compound the hypotensive effect
• B) Blockade of histamine H1 receptors produces sedation and psychomotor slowing -- risks amplified in the elderly by age-related reduction in hepatic CYP2D6 activity that prolongs antihistaminic effect; blockade of beta-1 adrenergic receptors produces bradycardia and reduced cardiac output -- risks amplified in the elderly by age-related reduction in intrinsic heart rate that leaves less compensatory margin against drug-induced slowing
• C) Blockade of muscarinic receptors at the sinoatrial node produces tachycardia that precipitates angina -- risks amplified in the elderly by the high prevalence of coronary artery disease; blockade of serotonin 5-HT2A receptors produces sleep fragmentation and REM suppression -- risks amplified by the normal reduction in sleep efficiency with age that makes serotonergic disruption particularly symptomatic
• D) Inhibition of the norepinephrine transporter (NET) produces hypertension and tachycardia that are poorly tolerated in elderly patients with hypertensive heart disease; inhibition of the serotonin transporter (SERT) produces platelet dysfunction and increased bleeding risk that is amplified by the high prevalence of concurrent anticoagulant and antiplatelet use in older adults
• E) Blockade of dopamine D2 receptors at the nigrostriatal pathway produces drug-induced parkinsonism -- risks amplified in the elderly by age-related reduction in dopaminergic neurons that reduces the threshold for extrapyramidal adverse effects; blockade of NMDA glutamate receptors produces dissociation and delirium that are amplified by the increased NMDA receptor sensitivity that develops with normal aging